Biogen’s New Boss Is Delivering, but Stock Isn’t Pricing It in Yet
The decision to buy Reata signals a new era under CEO Chris Viehbacher, and Wall Street’s skepticism presents an opportunity.
Saturday, April 18, 2026
Tag: BIIB
A Surprising Beneficiary of New Alzheimer’s Drugs: GE HealthCare
Biogen, Eli Lilly drugs will expand the imaging market for companies in the diagnostics space.
Alzheimer’s Blockbuster Is Coming, but Slowly
Developers of Alzheimer’s drugs have work cut out for them getting the treatments to patients.
Eli Lilly Results Signal Arrival of Blockbuster New Drug Class
ShareListen(2 min)
EDITOR'S PICK
:quality(70)/cloudfront-us-east-1.images.arcpublishing.com/tronc/6CHZI55G2AX4JYXPWLGHFBCWSE.jpg)
EP NEWSROOM
© 2025 Edinburg Post or its affiliated companies.